Winter Park, Florida--(Newsfile Corp. - December 29, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine, stem...
DaVita works with others in under-resourced communities to offer individualized health engagements, break down mistrust and empower action in personal...
PONTE VEDRA, FL / ACCESS Newswire / December 29, 2025 / Every industry has its forgotten corners. In anticoagulation, those...
Contract Research Organization for the REGAL trial has informed the Company that 72 events have occurred in the trial as...
Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (ORBIT) or bisphosphonates (COSMIC)...
Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (Orbit) or bisphosphonates (Cosmic)...
With legacy overhang removed and new capital secured, management shifts focus from balance-sheet repair to disciplined growth execution. West Palm...
VANCOUVER, British Columbia, Dec. 29, 2025 (GLOBE NEWSWIRE) -- via IBN -- Branded Legacy, Inc. (OTC:BLEG) under the leadership of...
Portland, Maine, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Most people believe dementia is a life sentence. Dr. Clint Steele once...
TOKYO, Dec. 29, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (Headquarters:Minato-ku, Tokyo; CEO: Kouji Eguchi; NASDAQ: MRM, MEDIROM or...
Company Announcement Genmab to discontinue clinical development of acasunlimab following a portfolio reviewDecision reflects prioritization of higher‑impact opportunities across Genmab’s...
Further validates continuation of the B-FREE Study to evaluate the efficacy and safety of ARAKODA® (tafenoquine) for treatment of chronic...
Proceeds to Support the Company’s Assessment of Opportunities to Advance BX011 and Ongoing Evaluation of Strategic AlternativesNESS ZIONA, Israel, Dec....
MINNEAPOLIS, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on...
CUPERTINO, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage...
The Breakthrough Therapy Designation was granted based on the positive topline results from the Essential3 Phase 3 program in essential...
- EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the first-line...
VANCOUVER, British Columbia, Dec. 29, 2025 (GLOBE NEWSWIRE) -- MedBright AI Investments Inc. (CSE: MBAI) (OTCQB: MBAIF) (FSE: Y30) (the...
Tiziana reports excellent safety profile with intranasal foralumab after 37.4 patient-years cumulative exposureFDA denial of Sanofi’s tolebrutinib for nrSPMS shows...
neffy is the first epinephrine product approved for use out of a hospital setting in China for adults and children...